A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa

Stopped early · Phase 1

Conditions studied: Retinitis Pigmentosa

In brief

The main purpose of this study is to evaluate the preliminary safety and immunogenicity (ability of an antigen to provoke immune response in the human body) of CNTO 2476, administered subretinally, in participants with advanced retinitis pigmentosa (RP; disease of the eye that leads to loss of vision and blindness) with either light perception only (LP) or hand motion (HM).

Key facts

Study ID

NCT00458575

Run by

Centocor, Inc.

People needed

7

Starts

2007-04-01

Expected to finish

2013-08-01

Last updated by the study team

2014-06-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed diagnosis of retinitis pigmentosa that is not part of another systemic disease
• Vision deficit characterized by vision that is not better than either light perception (Group 1) or hand motion (Group 2) in both eyes
• Normal hematology and chemistry lab results
• Participant is suitable candidate for ophthalmologic surgery

You may not qualify if…

• Other significant ophthalmologic diseases or any other ophthalmologic condition that interferes with ophthalmologic examination
• Women of childbearing potential
• Ocular hypertension
• Other serious medical conditions

Where it is running

• Study site — Miami, Florida, United States
• Study site — Southwest Portland, Oregon, United States
• Study site — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.